These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 37787749)

  • 21. First line treatment with newer tyrosine kinase inhibitors in chronic myeloid leukemia associated with deep and durable molecular response - systematic review and meta-analysis.
    Gurion R; Raanani P; Vidal L; Leader A; Gafter-Gvili A
    Acta Oncol; 2016; 55(9-10):1077-1083. PubMed ID: 27560448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy and safety of first-line tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review and network meta-analysis.
    Zhang JJ; Qian YL; Wu ZY; Li Y; Guan YJ; Sun C; Fu KL; Mei TL; Goyal G; Bernasconi P; Damiani D; Zhu JG
    Transl Cancer Res; 2024 Jul; 13(7):3783-3797. PubMed ID: 39145083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prevalence of Adverse Effects of Tyrosine Kinase Inhibitors Used in Management of Chronic Myeloid Leukemia at Sidi Bel-Abbès University Hospital Center].
    Matmour D; Si-Ali N; Benmehimda NC; Beloufa S; Belfrak F; Mahi E; Merad Y; Toumi H; Benlazar M
    Ann Pharm Fr; 2022 Nov; 80(6):932-942. PubMed ID: 35469781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
    Fujiwara SI; Shirato Y; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Int J Hematol; 2018 Jun; 107(6):712-715. PubMed ID: 29185155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted drugs in chronic myeloid leukemia.
    Gora-Tybor J; Robak T
    Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
    Jabbour E; Kantarjian H; Cortes J
    Semin Hematol; 2010 Oct; 47(4):344-53. PubMed ID: 20875551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.
    Moslehi JJ; Deininger M
    J Clin Oncol; 2015 Dec; 33(35):4210-8. PubMed ID: 26371140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia.
    Miura M
    Biol Pharm Bull; 2015; 38(5):645-54. PubMed ID: 25947908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pulmonary hypertension in patients with chronic myeloid leukemia.
    Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Sun BJ; Park JH; Jeong JO; Jo DY
    Medicine (Baltimore); 2021 Aug; 100(33):e26975. PubMed ID: 34414970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.
    Gover-Proaktor A; Granot G; Pasmanik-Chor M; Pasvolsky O; Shapira S; Raz O; Raanani P; Leader A
    Leuk Lymphoma; 2019 Jan; 60(1):189-199. PubMed ID: 29741440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
    Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
    Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.
    Smith BD; Brümmendorf TH; Roboz GJ; Gambacorti-Passerini C; Charbonnier A; Viqueira A; Leip E; Purcell S; Goldman EH; Giles F; Ernst T; Hochhaus A; Rosti G
    Leuk Res; 2024 Apr; 139():107481. PubMed ID: 38484432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia.
    Kim TD; Schwarz M; Nogai H; Grille P; Westermann J; Plöckinger U; Braun D; Schweizer U; Arnold R; Dörken B; le Coutre P
    Thyroid; 2010 Nov; 20(11):1209-14. PubMed ID: 20929406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors.
    Casavecchia G; Spinosa G; De Gennaro L; Zicchino S; Gravina M; Magnesa M; Di Biase M; Brunetti ND
    Acta Cardiol; 2022 Apr; 77(2):130-135. PubMed ID: 33685352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Syed YY; McCormack PL; Plosker GL
    BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular Toxicity Associated With Tyrosine Kinase Inhibitor Therapy In Chronic Myeloid Leukemia.
    Binzaid AA; Baqal OJ; Soheib M; Al Nahedh M; Samarkandi HH; Aljurf M
    Gulf J Oncolog; 2021 Sep; 1(37):79-84. PubMed ID: 35152199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Ota S; Matsukawa T; Yamamoto S; Ito S; Shindo M; Sato K; Kondo T; Kohda K; Sakai H; Mori A; Takahashi T; Ikeda H; Kuroda H; Haseyama Y; Yamamoto M; Sarashina T; Yoshida M; Kobayashi R; Nishio M; Ishihara T; Hirayama Y; Kakinoki Y; Kobayashi H; Fukuhara T; Imamura M; Kurosawa M
    Eur J Haematol; 2018 Jul; 101(1):95-105. PubMed ID: 29660177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
    Jain P; Kantarjian H; Boddu PC; Nogueras-González GM; Verstovsek S; Garcia-Manero G; Borthakur G; Sasaki K; Kadia TM; Sam P; Ahaneku H; O'Brien S; Estrov Z; Ravandi F; Jabbour E; Cortes JE
    Blood Adv; 2019 Mar; 3(6):851-861. PubMed ID: 30885996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
    Quintás-Cardama A; Cortés JE; Kantarjian H
    Clin Lymphoma Myeloma; 2008 Mar; 8 Suppl 3():S82-8. PubMed ID: 19254885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.